

GENERAL INFORMATION

REGISTRATION FEES¹⁾

Delegates from	Members ²⁾	Other
Industry	965 €	980 €
Academia	665 €	680 €

1) No VAT requested according to § 4.22 UStG.

2) Personal DECHEMA-, APV-members and EFC/EFCE passport holders

The registration fee includes the book of abstracts, the list of participants and the food and drinks during the breaks.

CANCELLATION AND REFUNDS

30 € administration costs will be charged for cancellations of registrations by **1 October 2015**. Thereafter 80% of the registration fee will be charged. Only written cancellations will be accepted. Conference fees can neither be waived nor refunded in case of no-shows.

If the event is cancelled by DECHEMA the registration fees for the conference will be refunded. Further claims for compensation are excluded.

LANGUAGE

The conference language is English.

DATES TO NOTE

June 2015 Programme available
July 2015 Online registration opens

SOCIAL EVENT

Conference Dinner at the Restaurant Gerbermuehle – one of the most historically important spots at the banks of river main, Frankfurt.
Price 120 € (incl. dinner, beverages, transport to and from the restaurant)




GENERAL INFORMATION

VENUE

DECHEMA-Haus
Theodor-Heuss-Allee 25
60486 Frankfurt am Main
Germany

Directions to DECHEMA: www.dechema.de/en/directions



ACCOMMODATION

Information about accommodation is available at www.dechema.de/DrugEng2015

ORGANISER

DECHEMA e. V.
Theodor-Heuss-Allee 25
60486 Frankfurt am Main
Germany

CONTACT

Petra Hellwig
Phone: +49 (0)69 7564-167
Fax: +49 (0)69 7564-176
E-mail: hellwig@dechema.de

www.dechema.de/DrugEng2015




INVITATION AND PROGRAMME

12 – 13 November 2015
DECHEMA-Haus · Frankfurt am Main · Germany

Material Science and Engineering in Drug Development

www.dechema.de/DrugEng2015



© Juulijis - Fotolia



INVITATION

Over more than the last two decades intense research was conducted in materials science aspects of small molecule drug substances and it is now well understood that the solid state form and the properties of the solid state form of an API play an important role in drug development and drug substance and drug product manufacturing.

The choice of the optimal crystalline form, polymorph, crystal size and or the choice of an amorphous form determines both the performance of the drug product such as bioavailability or stability and the stability of the formulation process.

An early and substantial decision on the right form will facilitate and speed up the development process and help avoid late stage surprises and needs for late stage changes.

This process requires both a sound characterization of the properties of the moiety under consideration as well as a sound knowledge on the possibilities and limitations of engineering the particle properties and last but not least knowledge on the influence of the particle properties on the formulation behaviour as well as the capability to characterize these properties. Here the interplay of lab based and in silico data generation and interpretation will play a growing role to quickly and reliably decide on the solid form of a given API early in the pharmaceutical development process.

The conference will discuss all relevant aspects of this topic and recent advances in this field, focussing on pre-competitive aspects.

The presentations will discuss the current status and options of particle characterization and of particle design to meet the demands of formulation and the multitude of demands of modern formulations on the properties of the solid state form supplied.

A panelled discussion will be used to further the field and give input for further research.

TOPICS

- » Multiplicity of solid state forms: molecule to solid state chemistry
- » Scientific aspects of solid-state engineering: crystal chemistry to particle and surface chemistry
- » Current status of molecular modelling aspects of materials science
- » Formulation aspects of material science and engineering
- » Material science aspects of solid-solutions of API's
- » Control strategies of solid state form API attributes in formulation – impact on product

PROGRAMME

Thursday, November 12, 2015

10:00	Welcome and introductory remarks W. Beckmann, Bayer Technology Services GmbH, Leverkusen/D	
		<i>set the theme</i>
10:10	Following the particles on their journey from crystallizer to patient C. Price, University of Strathclyde, Glasgow/UK	
		<i>design the form</i>
11:10	Selection of Solid-State forms for new chemical entities: challenges, opportunities and lessons learned C. Saal, Merck KGaA, Darmstadt/D	
12:00	Hydrate phases in pharmaceutical development N. Nagel, Sanofi-Aventis Deutschland GmbH, Frankfurt/D	
12:50	Lunch Break	
	Scientific aspects of solid-state engineering	<i>design the particle</i>
14:00	Polymorphism and solvate formation – potential threats in pharmaceutical industry D. Wieckhusen, Novartis Pharma AG, Basel/CH	
14:50	The role of API surface chemistry in pharmaceutical processes J. Heng, Imperial College London/UK	
15:40	Solid form design & crystal habit modification: utilizing crystallographic data to guide experimental design S. Chan, Novartis Pharma AG, Basel/CH	
16:30	Coffee Break	
	Molecular modelling aspects of materials science	<i>support via modelling</i>
16:50	Exploring solid forms landscapes with structural informatics N. Feeder, CCDC, Cambridge/UK	
17:40	From Molecules to Crystals: Modelling across the Solid State Landscape A. Florence, CMAC – University of Strathclyde, Glasgow/UK	
18:30	End-of-day-1	
20:00	Conference Dinner at Restaurant Gerbermuehle Gerbermuehlstrasse 105, 60594 Frankfurt	

PROGRAMME

Friday, November 13, 2015

	Formulation aspects of material science and engineering – control of the API physical form	<i>secure the API attributes</i>
8:30	Integrated crystal and particle engineering for developing pharmaceutical tablet C. Sun, University of Minnesota, Minneapolis, MN/USA	
9:20	The role of particle engineering in formulation design – link between drug substance and drug product R. Storey, AstraZeneca R&D, Macclesfield/UK	
10:10	Coffee Break	
		<i>panelled discussion</i>
10:30	Current topics of material science engineering in drug development and manufacturing J.-O. Henck – C. Price – W. Beckmann – N. Nagel – L. Yu	
12:00	Lunch Break	
	Material science aspects of solid-solutions of API's	<i>amorphous materials</i>
13:00	Amorphous organic materials L. Yu, University of Wisconsin, Madison, WI/USA	
13:50	Industrial perspectives of manufacturing solid dispersions as enabling technology – from early development to commercial manufacturing G. Verreck, Johnson & Johnson Pharma R&D, Beerse/B	
14:40	Coffee Break	
	Control strategies of solid state form API attributes in formulation	<i>performance impact on product</i>
15:00	Small-scale approaches for supporting the solid form selection J. Rantanen, University of Copenhagen/DK	
15:50	What are the critical attributes of APIs which influences formulation microstructure and dominates product functionality ? R. Price, University of Bath/UK	
16:40	Connecting the API solid form and particle to drug product performance M. Ticehurst, Pfizer, Canterbury/UK	
17:30	End and farewell	